

China Biologic Products, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

https://marketpublishers.com/r/C46C218D5AEBEN.html

Date: May 2025 Pages: 50 Price: US\$ 499.00 (Single User License) ID: C46C218D5AEBEN

Abstracts

China Biologic Products, Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between China Biologic Products, Inc. and its competitors. This provides our Clients with a clear understanding of China Biologic Products, Inc. position in the Pharmaceuticals and Biotechnology Industry.

The report contains detailed information about China Biologic Products, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for China Biologic Products, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The China Biologic Products, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios



pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes China Biologic Products, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of China Biologic Products, Inc. business.

About China Biologic Products, Inc.

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in China.

The company operates primarily, through its indirect majority owned Chinese subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Qianfeng Biological Products Co., Ltd. and minority owned Chinese subsidiary, Xi'an Huitian Blood Products Co., Ltd.

Products

The company's principal products are its approved human albumin and immunoglobulin products. It is approved to produce 16 biopharmaceutical products in 8 major categories, including Human Albumin: - 20%/10ml, 20%/25ml, 20%/50ml, 10%/10ml, 10%/25ml, 10%/50ml and 25%/50ml; Human Hepatitis B Immunoglobulin – 100 International Units, or IU, 200IU, 400IU; Human Immunoglobulin – 10%/3ml and 10%/1.5ml; Human Immunoglobulin for Intravenous Injection – 5%/25ml and 5%/50ml; Human Immunoglobulin-5g/vial; Thymopolypeptides Injection – 20mg/2ml,5mg/2ml;



Thymopolypeptides Injection – 20mg/2ml,5mg/2ml; and Thymopolypeptides Injection – 20mg/2ml,5mg/2ml.

Human albumin is principally used to increase blood volume while immunoglobulin is used for certain disease preventions and cures. Albumin is also used to treat critically ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. The company's approved human albumin and immunoglobulin products use human plasma as the basic raw material. All of its approved products are prescription medicines administered in the form of injections.

Customers

The company's customers include Handan Zhiying Medical Company; Guizhou Guotai Medical Company; Sichuan Shannuoyi Medical Company; Zibo KangHua Medical Supply Company; and Synergy Diagnostics PVT Limited. It sells its products to hospitals and inoculation centers.

Suppliers

The company's suppliers include Sansui Plasma Station; Chongqing Sanda Weiye Pharmaceutical Products; Sichuan Nangeer Biological Medical Company; Zibo Zhong Bao Kang Medical Equipment Company; Tai'an City Ruifeng Company; Beijing Wantai Biological Pharmacy Enterprise; Guizhou Sanling Chemical Technology Service Company; Shandong Medical Bottling Company; Beijing Zhongtianbaiyi Technology Development Company; and Wenzhou City Jiacheng Printing Company.

Competition

The company's major competitors in the albumin and immunoglobulin market in China are Hua Lan Biological Engineering, Shanghai Institute of Biological Products, Shanghai RAAS Blood Products Co. Ltd., Beijing Tiantan Biological Products, and Sichuan Yuanda Shuyang Pharmaceutical Co.

History

China Biologic Products, Inc. was founded in 1971.

The above Company Fundamental Report is a half-ready report and contents are subject to change.



It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.



Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. CHINA BIOLOGIC PRODUCTS, INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. CHINA BIOLOGIC PRODUCTS, INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. CHINA BIOLOGIC PRODUCTS, INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. CHINA BIOLOGIC PRODUCTS, INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
- 4.1.1. Income Statement
- 4.1.2. Balance Sheet
- 4.1.3. Cash Flow
- 4.2. Financial Ratios
- 4.2.1. Profitability
- 4.2.2. Margin Analysis



- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. CHINA BIOLOGIC PRODUCTS, INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. China Biologic Products, Inc. Direct Competitors

5.2. Comparison of China Biologic Products, Inc. and Direct Competitors Financial Ratios

- 5.3. Comparison of China Biologic Products, Inc. and Direct Competitors Stock Charts
- 5.4. China Biologic Products, Inc. Industry Analysis
- 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
- 5.4.2. China Biologic Products, Inc. Industry Position Analysis

6. CHINA BIOLOGIC PRODUCTS, INC. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. CHINA BIOLOGIC PRODUCTS, INC. EXPERTS REVIEW¹

- 7.1. Experts Consensus
- 7.2. Experts Revisions

8. CHINA BIOLOGIC PRODUCTS, INC. ENHANCED SWOT ANALYSIS²

9. CHINA PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors



10. CHINA BIOLOGIC PRODUCTS, INC. IFE, EFE, IE MATRICES²

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

11. CHINA BIOLOGIC PRODUCTS, INC. PORTER FIVE FORCES ANALYSIS²

12. CHINA BIOLOGIC PRODUCTS, INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

China Biologic Products, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit Profit Margin Chart Operating Margin Chart Return on Equity (ROE) Chart Return on Assets (ROA) Chart Debt to Equity Chart Current Ratio Chart China Biologic Products, Inc. 1-year Stock Charts China Biologic Products, Inc. 5-year Stock Charts China Biologic Products, Inc. 5-year Stock Charts China Biologic Products, Inc. vs. Main Indexes 1-year Stock Chart China Biologic Products, Inc. vs. Direct Competitors 1-year Stock Charts China Biologic Products, Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses. The complete financial data is available for publicly traded companies.



List Of Tables

LIST OF TABLES

China Biologic Products, Inc. Key Facts Profitability Management Effectiveness Income Statement Key Figures **Balance Sheet Key Figures Cash Flow Statement Key Figures Financial Performance Abbreviation Guide** China Biologic Products, Inc. Key Executives China Biologic Products, Inc. Major Shareholders China Biologic Products, Inc. History China Biologic Products, Inc. Products Revenues by Segment Revenues by Region China Biologic Products, Inc. Offices and Representations China Biologic Products, Inc. SWOT Analysis Yearly Income Statement Including Trends Income Statement Latest 4 Quarters Including Trends Yearly Balance Sheet Including Trends Balance Sheet Latest 4 Quarters Including Trends Yearly Cash Flow Including Trends Cash Flow Latest 4 Quarters Including Trends China Biologic Products, Inc. Profitability Ratios Margin Analysis Ratios Asset Turnover Ratios **Credit Ratios** Long-Term Solvency Ratios Financial Ratios Growth Over Prior Year China Biologic Products, Inc. Capital Market Snapshot China Biologic Products, Inc. Direct Competitors Key Facts **Direct Competitors Profitability Ratios Direct Competitors Margin Analysis Ratios Direct Competitors Asset Turnover Ratios Direct Competitors Credit Ratios Direct Competitors Long-Term Solvency Ratios** Pharmaceuticals and Biotechnology Industry Statistics



China Biologic Products, Inc. Industry Position Company vs. Industry Income Statement Analysis Company vs. Industry Balance Sheet Analysis Company vs. Industry Cash Flow Analysis Company vs. Industry Ratios Comparison China Biologic Products, Inc. Consensus Recommendations¹ Analyst Recommendation Summary¹ Price Target Summary¹ Experts Recommendation Trends¹ Revenue Estimates Analysis¹ Earnings Estimates Analysis¹ Historical Surprises¹ Revenue Estimates Trend¹ Earnings Estimates Trend¹ Earnings Estimates Trend¹ Revenue Revisions¹



ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.



Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors



integrated into one suggestive model.

Porter Five Forces Analysis

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources Financial

Physical

Technological

Organizational

Intangible resources Human

Innovation and Creativity



Reputation

Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?



I would like to order

Product name: China Biologic Products, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: https://marketpublishers.com/r/C46C218D5AEBEN.html

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/C46C218D5AEBEN.html</u>